ASX-listed health tech firm CardieX announced its subsidiary, medical technology company ATCOR, will partner with AI-enabled health tech company Invaryant to conduct joint clinical research on maternal health and cardiovascular disease.
Invaryant's health platform will integrate digital vascular biomarkers gathered from ATCOR's SphygmoCor arterial technology, which measures the central aortic...
ASX-listed health tech firm CardieX announced it acquired Silicon Valley-based Blumio, a developer of cardiovascular sensor algorithms and data analytics tools.
CardieX focuses on hypertension, cardiovascular health and other arterial health disorders, while Blumio develops wearable-sensor technologies focused on capturing cardiovascular data, including blood pressure measurements.
The...
CardieX files 510(k) for dual blood pressure, arterial health monitor
Australia-listed health tech firm CardieX has filed a 510(k) premarket submission with the US Food and Drug Administration for its dual blood pressure and arterial health monitor.
Called the CONNEQT Pulse, the health monitor features CardieX's FDA-cleared SphygmoCor technology which measures central blood pressure to obtain...
